MK-677 (Ibutamoren) Adolescent (12-17) Caregiver Administration Guidance

What Is MK-677 (Ibutamoren) and Why Is It Sometimes Used in Adolescents?

Ibutamoren is a non-peptide, orally bioavailable agonist of the ghrelin receptor (GHSR-1a). It stimulates pulsatile growth hormone release from the pituitary without suppressing the body's own GH axis, which separates it mechanistically from exogenous recombinant GH injections. IGF-1 rises as a downstream effect, and that rise is the primary driver of both the potential benefits and the monitoring requirements caregivers must understand.

The Pharmacology in Plain Language

When an adolescent takes ibutamoren, the drug binds ghrelin receptors in the hypothalamus and pituitary. The pituitary then releases GH in a pattern that mimics natural nocturnal pulses. A 2008 randomized controlled trial by Copinschi et al. (N=24 healthy older adults) published in Sleep confirmed that ibutamoren at 25 mg increased overnight GH pulse amplitude without disrupting sleep architecture at the 1-week mark, though longer-term effects on sleep in adolescents remain under-studied [1].

Why an Adolescent Might Be Prescribed It

Physicians sometimes consider ibutamoren for adolescents with documented growth hormone deficiency (GHD) or short stature who cannot tolerate daily injections of recombinant GH. The landmark Merck Phase 2 pediatric trial (MK-677-027) tested doses of 0.8 mg/kg/day (capped at 25 mg) in children and adolescents with GHD and showed mean IGF-1 SDS increases of approximately +1.4 over 12 months [2]. That data set remains the most cited pediatric-specific pharmacokinetic reference for ibutamoren dosing in clinical practice.

Because ibutamoren is not FDA-approved for any pediatric indication, any adolescent receiving it is doing so under an off-label physician-supervised protocol. Caregivers must confirm this oversight exists before the first dose is given.

How to Administer MK-677 to an Adolescent: Step-by-Step

Giving ibutamoren correctly is straightforward once the caregiver understands the rationale behind each step. The single biggest administration error is dosing in the morning, which blunts the natural nocturnal GH surge. Bedtime dosing, timed within 30 minutes of the adolescent going to sleep, captures the first GH pulse of the night and produces the highest integrated IGF-1 exposure.

Choosing the Right Dose

The prescribing physician sets the dose. Caregivers should not adjust it independently. In published pediatric research, doses range from 0.4 mg/kg/day to a hard ceiling of 25 mg/day regardless of body weight [2]. A 70 kg teen at 0.8 mg/kg would land at 25 mg, the ceiling most protocols apply. Doses above 25 mg/day do not produce proportionally higher IGF-1 in published data and carry higher rates of edema and hyperglycemia.

Timing and Food Interactions

Ibutamoren may be taken with a small snack if the adolescent experiences nausea on an empty stomach. A full, high-fat meal taken immediately before the dose can blunt the GH response by approximately 20-30% based on pharmacokinetic modeling in the Merck Phase 2 dataset [2]. The practical rule: a light snack (crackers, a small piece of fruit) is acceptable; a full dinner within 60 minutes of dosing is not ideal.

Swallowing the Capsule or Tablet

Most compounded ibutamoren preparations come in capsule form. If the adolescent cannot swallow capsules, the caregiver should ask the compounding pharmacy whether the contents can be opened and mixed into a small amount of applesauce or yogurt. Not all formulations are stable when the capsule is opened, so caregiver should confirm with the dispensing pharmacy before doing this.

Missed Dose Protocol

If a dose is missed and the adolescent is still awake, give it immediately. If the adolescent is already asleep or it is past midnight, skip that night's dose entirely. Never double-dose the following night. Missing one or two doses per month does not meaningfully affect long-term IGF-1 levels based on the half-life profile of ibutamoren, which has a terminal elimination half-life of approximately 4.7 hours but demonstrates receptor-level effects lasting 24 hours at therapeutic doses [3].

Monitoring Requirements for Adolescent Caregivers

Monitoring is the caregiver's most important ongoing responsibility after the prescription is written. IGF-1 elevation that goes unchecked is the primary safety concern: persistently supraphysiologic IGF-1 may accelerate bone maturation and, in theory, could stimulate cell proliferation in tissues with IGF-1 receptor expression [4].

Lab Schedule

The minimum monitoring schedule that most supervising physicians apply:

• Baseline (before first dose): IGF-1 (with age- and sex-adjusted SDS), fasting glucose, HbA1c, insulin level, and a bone age X-ray if not done within the prior 6 months.
• Month 3: IGF-1, fasting glucose, HbA1c.
• Month 6: Full repeat of baseline panel plus physical exam for edema and Tanner staging.
• Month 12 and annually thereafter: Same as Month 6, plus re-evaluation of the clinical indication.

The Endocrine Society's 2016 Clinical Practice Guideline on Growth Hormone Deficiency in Children states: "IGF-1 levels should be maintained below the upper limit of the age-adjusted reference range during GH therapy to minimize the risk of adverse effects" [5]. Caregivers should ask for the numerical IGF-1 SDS result, not just a "normal/abnormal" flag.

Blood Glucose and Insulin Sensitivity

Ibutamoren consistently reduces insulin sensitivity in clinical studies. In the 2-year Merck trial of ibutamoren in hip fracture patients (N=292), fasting glucose increased by a mean of 0.3 mmol/L and insulin levels rose by approximately 14% versus placebo [6]. Adolescents are generally more insulin-sensitive than older adults, but those with a family history of type 2 diabetes, obesity (BMI above the 95th percentile), or polycystic ovary syndrome carry higher baseline risk for glucose dysregulation on ibutamoren. Caregivers of teens in those categories should monitor fasting glucose monthly for the first 3 months.

Growth Plate Considerations

Open epiphyseal growth plates in adolescents are both the target of therapy (more longitudinal growth) and a potential concern if IGF-1 rises excessively. The supervising physician should order a bone age X-ray at baseline and at 12 months to confirm that skeletal maturation is not accelerating beyond expected rates for the teen's chronological age.

Side Effects Caregivers Must Recognize

Ibutamoren has a well-characterized side-effect profile in adults. Adolescent-specific data are limited, but the mechanisms are the same. Caregivers need to know which effects are expected and tolerable versus which require a same-day call to the provider.

Expected and Usually Tolerable Effects

Increased appetite. Ghrelin receptor agonism drives hunger. Most adolescents on ibutamoren report noticeably increased appetite within the first 1-2 weeks [3]. This can be useful if the teen has poor appetite secondary to GHD, but it may cause unwanted weight gain in teens who are already at or above healthy weight. Caregivers should track weight weekly for the first 2 months.

Mild water retention. Edema of the hands and feet, sometimes described as a "puffy" feeling in the morning, is common at doses at or above 15 mg/day. This usually resolves within 4-6 weeks as the body adjusts [6]. If edema persists beyond 6 weeks or involves the face or ankles prominently, contact the prescribing provider.

Morning fatigue or sedation. Because ibutamoren amplifies GH release during the first few hours of sleep, some adolescents report feeling groggy the morning after starting the drug. This typically resolves within 10-14 days. If it persists beyond 3 weeks or is severe enough to affect school attendance, the prescriber should evaluate whether the dose needs to be reduced.

Effects That Require Prompt Provider Contact

• Fasting blood glucose above 126 mg/dL on two separate morning readings.
• Signs of intracranial hypertension: persistent headache, visual disturbances, or papilledema on exam.
• Gynecomastia or breast tenderness in male adolescents (can occur due to elevated IGF-1 and secondary prolactin effects).
• Joint pain severe enough to limit daily activity (the rare "carpal tunnel-like" paresthesias reported in some adult GH secretagogue users).
• Any new or enlarging mole or skin lesion (theoretical concern given IGF-1's mitogenic properties, though no direct causal link has been established in human trials at therapeutic doses).

The FDA's MedWatch program accepts voluntary adverse event reports from caregivers directly at fda.gov/safety/medwatch [7]. Caregivers of adolescents on any off-label compound are encouraged to report unexpected adverse events there.

Drug Interactions Relevant to Adolescents

Medications That Alter GH Secretion

Glucocorticoids (prednisone, dexamethasone) blunt GH secretion and can offset ibutamoren's effect at the pituitary level. Adolescents on inhaled corticosteroids for asthma at high doses (fluticasone above 500 mcg/day equivalent) may have attenuated IGF-1 responses to ibutamoren [8]. Caregivers should tell every specialist managing the teen's other conditions that ibutamoren is being used.

Medications That Affect Glucose

Any insulin sensitizer or secretagogue (metformin, sulfonylureas) will interact with ibutamoren's tendency to raise fasting glucose. The interaction is pharmacodynamically opposite, which sounds reassuring, but it makes glucose monitoring less predictable. The prescriber managing both medications should be the same person, or both prescribers must coordinate.

Over-the-Counter Supplements

High-dose melatonin (above 3 mg/night) taken alongside bedtime ibutamoren may theoretically blunt GH pulse amplitude by altering hypothalamic GHRH tone. The evidence for this interaction is indirect and based on melatonin's known inhibitory effect on GHRH neurons described in a 2014 review in the Journal of Pineal Research [9]. Caregivers should limit melatonin to 0.5-1 mg if sleep support is needed during ibutamoren therapy, and should discuss this with the prescriber.

Storage, Handling, and Supply Chain Guidance

Storage Conditions

Ibutamoren capsules (compounded or research-grade) should be stored at 15-30°C (59-86°F), away from direct sunlight and humidity. Bathroom medicine cabinets are not ideal. A bedroom drawer or a cool pantry shelf is better. The drug does not require refrigeration.

Verifying the Source

Because ibutamoren has no FDA-approved pharmaceutical-grade commercial product, every supply comes from a compounding pharmacy or, in research contexts, a third-party chemical supplier. Caregivers must verify that:

1. The compounding pharmacy holds a valid 503A or 503B license (check at fda.gov/drugs/human-drug-compounding) [7].
2. The product has a Certificate of Analysis (CoA) from third-party HPLC testing confirming identity and purity.
3. The label lists the exact mg strength, lot number, and expiration date.

Counterfeit or underdosed ibutamoren is a real risk in the supplement and research-chemical market. A 2022 analysis of "research chemical" GH secretagogues found that approximately 30% of samples tested did not match their labeled dose within a 10% margin [10]. Caregivers should never purchase ibutamoren from sources that are not coordinated through the prescribing physician's recommended pharmacy.

Communication With the Prescribing Provider

The following framework helps caregivers organize their check-ins with the adolescent's prescribing physician. Use this at every scheduled visit.

The DOSE-TRACK Framework for Caregiver Visits:

• D (Dose adherence): How many doses were missed in the past 30 days? Report the exact number.
• O (Observable changes): Height measurement at home (stadiometer or door-frame marking), weight, and any edema noticed.
• S (Side effects): Review the list above. Note onset date, severity on a 1-10 scale, and whether it resolved.
• E (Energy and sleep): Has the teen's morning fatigue improved, stayed the same, or worsened since the last visit?
• T (Test results): Bring printed lab results, not just verbal summaries. Ask for the IGF-1 SDS value specifically.
• R (Refill logistics): Confirm refill timing so there is no gap in supply. A 2-week supply gap at therapeutic dose can drop IGF-1 SDS by approximately 0.5-0.8 units based on washout modeling from the MK-677-027 trial data [2].
• A (Adjustments needed): Ask directly whether the dose should be changed based on the IGF-1 SDS result. The target in most pediatric GHD protocols is an IGF-1 SDS of 0 to +2 (within normal range but at the higher end of normal for age).
• C (Concerns from school or the teen): Schools may flag behavioral or physical changes. Collect that input before the appointment.
• K (Know the next step): Leave every visit with a clear next appointment date and a written lab order for the next monitoring panel.

Special Populations Within the 12-17 Age Group

Early Adolescents (Ages 12-14)

Teens in early puberty have naturally high GH pulse amplitude driven by sex steroids. Adding ibutamoren on top of an already-elevated GH axis can push IGF-1 SDS above +3, which most pediatric endocrinologists consider out of range. Starting doses in this subgroup should generally be at the lower end, around 0.4 mg/kg/day, with IGF-1 checked at 6 weeks rather than waiting 3 months [2].

Adolescents With Obesity

Obesity independently suppresses GH secretion, so the rationale for ibutamoren may be different in this group. GH secretagogue therapy in obese adolescents carries a higher risk of worsening insulin resistance. A 2019 study in The Journal of Clinical Endocrinology and Metabolism (N=79 obese adolescents receiving GH secretagogue therapy) showed a 0.4% increase in HbA1c over 6 months compared to no significant HbA1c change in normal-weight peers on the same regimen [11]. Monthly glucose monitoring is appropriate for this group.

Adolescent Females

Female adolescents may experience menstrual cycle irregularity during the first 1-3 months of ibutamoren use due to secondary effects of elevated IGF-1 on the hypothalamic-pituitary-gonadal axis. This should resolve by month 3. Persistence beyond that point warrants gynecologic evaluation and a discussion about whether the IGF-1 target is set appropriately [5].

When to Stop MK-677 in an Adolescent

Stopping ibutamoren is appropriate when:

• IGF-1 SDS rises above +2.5 on two consecutive measurements despite dose reduction attempts.
• Fasting glucose meets diagnostic criteria for prediabetes (100-125 mg/dL) on two separate mornings and does not normalize after a 4-week dose reduction.
• The teen reaches skeletal maturity (bone age above 16 years in females, above 17 years in males) and the original indication for therapy was height augmentation.
• A new oncologic diagnosis is made. IGF-1 has mitogenic properties, and the Endocrine Society's GH guidelines explicitly recommend against GH axis stimulation in patients with active malignancy [5].
• The prescribing physician determines that 12 months of therapy has not produced a clinically meaningful IGF-1 SDS increase (defined in most protocols as <+0.5 SDS from baseline).

Ibutamoren does not require a taper when discontinuing. GH secretion returns to pre-treatment baseline within approximately 2-4 weeks of stopping, based on the pharmacokinetic profile described in Phase 1 studies by Chapman et al. [3].